Clinical trials: Resolution
Tinea Pedis
Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis
This study will compare the efficacy and safety of a single dose of terbinafine film forming solution 1% with a single dose of placebo film forming solution in the treatment of tinea pedis.
- Trial name
- NCT01433107
- Testing
- Terbinafine
- Where
- 6 sites in China
- Volunteers
- 290 people
- Sponsor
- Novartis
Bronchiectasis
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3…
- Trial name
- AIR-BX2 (NCT01314716)
- Testing
- AZLI
- Where
- 85 sites in United States, Australia and 8 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Surgical Remove of Hemorrhoids
Safety and Efficacy of the Addition of Morphine Chloride to a Low Dose of Bupivacaine as Intradural Anaesthetic for the Removal Surgery of the Hemorrhoids
A single blind, randomized, with blinded evaluation by third parties clinical trial is carried out to assess the analgesic efficay of the addition of morphine chloride to a low dose solution of spinal local anaesthetic compared…
- Trial name
- NCT02046772
- Testing
- Bupivacaine low dose, Bupivacaine standard dose, Morphine Chloride
- Where
- 2 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Nervous System Diseases
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.
- Trial name
- NCT03336645
- Testing
- SHP615
- Where
- 23 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Shire
Dry Eye Syndrome
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry…
- Trial name
- NCT03404115
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye Syndrome
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
The purpose of this study is to evaluate the efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.
- Trial name
- PRO-148 (NCT01541891)
- Testing
- PRO-148 Ophthalmic Solution, Active Comparator: SYSTANE ® Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Inflammation, Pseudophakia
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
This is a single-center, randomized, investigator-masked, parallel group, and active-comparator controlled study investigating the clinical outcomes for visual acuity and macular thickness after treatment with Bromday (bromfenac…
- Trial name
- NCT01310127
- Testing
- Bromfenac, Nepafenac
- Volunteers
- 23 people
- Sponsor
- Toyos Clinic
Healthy
TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants
The purpose of this study is to assess the relative bioavailability of solid oral formulations of TAK-020 in comparison with single dose of TAK-020 oral solution formulation and to evaluate the food effect and potentially the…
- Trial name
- NCT02723201
- Testing
- TAK-020 Captisol Oral Solution, TAK-020 CCT, TAK-020 SDT
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via pre-filled syringe compared to mirikizumab (reference)…
- Trial name
- NCT05644353
- Testing
- Mirikizumab
- Where
- 6 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Iron-Refractory Iron-Deficiency Anemia
Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol
The main purpose is to determine whether Triferic, administered orally with Shohl's solution, is safe and effective for the treatment of iron-refractory iron-deficiency anemia (IRIDA).
- Trial name
- NCT02905981
- Testing
- Fer-In-Sol, Shohl's solution, Triferic
- Volunteers
- 1 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on…
- Trial name
- NCT01634152
- Testing
- Tiotropium low dose mcg, Tiotropium high dose
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 401 people
- Sponsor
- Boehringer Ingelheim
Allergic Conjunctivitis
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
- Trial name
- NCT03489941
- Testing
- EM-100, Zaditor®, Vehicle
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Bausch & Lomb Incorporated
Androgenetic Alopecia
Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
The purpose of this study is evaluating the efficacy and safety of a topical herbal solution in males for the treatment of Androgenetic alopecia.
- Trial name
- NCT03753113
- Testing
- Topical Herbal Solution, Topical Minoxidil 5%
- Where
- Iran
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Farid Masoud
Refractive Errors
Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations
The purpose of this study is to evaluate corneal staining observed after 2 hours of wear with an investigational contact lens against both PureVision contact lenses pre-cycled with Biotrue and Biofinity contact lenses pre-cycled…
- Trial name
- NCT04789382
- Testing
- LID018869+RepleniSH, LID018869+Biotrue, Biofinity+RepleniSH
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Alcon Research
Dry Eye
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
Study design: Phase I clinical trial, single-center, controlled, parallel group, open, randomized. Number of subjects: n = 34 evaluable subjects, 17 evaluable subjects per group (both eyes).
- Trial name
- PRO-037 (NCT04081610)
- Testing
- lagricel ofteno multidose, lagricel ofteno single dose
- Where
- Mexico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Pterygium
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
- Trial name
- Pterygium (NCT03049852)
- Testing
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cloudbreak Therapeutics, LLC
Ischemia Reperfusion Injury
Purge Vs no Purge in Living Donor Liver Transplantation Recipients
The investigators tested the impact of purging the graft contents and mesenteric blood into the systemic circulation versus washing out this volume out of the circulation in living donor liver transplantation recipients.
- Trial name
- PNP (NCT02540447)
- Testing
- Purge
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Head and Neck Carcinoma, Radiation-Induced Dermatitis
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized phase 3 trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation…
- Trial name
- NCT02369835
- Testing
- Dakin's solution
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Stanford University
Healthy
A Study of Two Different Formulations of LY3074828 in Healthy Participants
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations.
- Trial name
- NCT03188510
- Testing
- LY3074828
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dry Eye
Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05467293
- Testing
- 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 257 people
- Sponsor
- Yuyu Pharma, Inc.